CD8A and hepatocellular carcinoma: Guo et al. analyzed hepatocellular carcinoma patients treated with anti-PD-1 and lenvatinib, identifying a circulating CD8+ T cell population that plays a crucial role in treatment efficacy (Guo et al., 2025).